Gilead reports 2Q13 earnings

Gilead Sciences Inc. (NASDAQ:GILD) reported 2Q13 non-GAAP diluted EPS of $0.50, meeting the Street's estimate and up a penny from $0.49 in 2Q12. Total revenues for the quarter were $2.77 billion, up 15% from $2.4 billion in 2Q12. Product sales in the quarter were $2.66 billion, up 14% from $2.32 billion in the prior year's quarter. The Street was expecting $2.66 billion in revenues. The company reported $99.4 million in worldwide sales of HIV drug Stribild elvitegravir/ cobicistat/emtricitabine/tenofovir (formerly Quad), which the European Commission approved in May. FDA approved the once-daily tablet last August. ...